1. IMS LifeCycle R&D Focus New Product Focus Patent Focus Content, Sources & Updates SLA Pharmaceutical & Health Technology Division Spring Meeting
3/27/2017

2. Introduction
IMS LifeCycle • 3/27/2017 2

3. The LifecCycle Training Course Introduction
IMS LifeCycle • 3/27/2017 3
Page:
27/03/2017

4. R&D Focus - Introduction
This IMS service provides in-depth profiles on over 26,000 drugs in R&D, from preclinical to marketed phases, including commercial and scientific activities.
R&D Focus is part of IMS LifeCycle, which enables the reviews of a drug life cycle at three critical stages: R&D stages, launch activities and patent protection worldwide.
IMS LifeCycle • 3/27/2017 4

5. R&D Focus Statistics
Over 26,000 records including over 9,700 drugs in active R&D worldwide
Searches on 36 fields including mode of administration, mechanism of action, indication, phases of development
Covers over 5,600 Biotechnology products
More than 3,000 companies/organisations
Over 3,200 licensing opportunities
Company coverage is global (focus on the USA and Europe):
Europe: 30%
The Americas: 51%
Middle East: 3%
Asia Pacific: 13%
Australasia: 3%
Up to 800 updates every month, and up to 100 new drugs added every month
IMS LifeCycle • 3/27/2017 5

6. The LifecCycle Training Course Introduction
R&D Focus Data Content
Compound details/Chemical structures
Latest development information (“Latest News”)
Company activities (developers, licensors, licensees relationships)
Latest phase including Discovery and Technology stages and phase by country and indication
Around 1,900 indications (i.e. Breast Cancer to Zollinger-Ellison syndrome)
Over 750 pharmacological actions (i.e. ACE inhibitors or 5HT4 antagonist)
Sales profiles for the top or fastest growing therapeutic classes, featuring previous years background financial info
Basic patent information (initial priority details)
Commercial/scientific summary, including regulatory progress, clinical trials, analysts predictions
Development history
IMS LifeCycle • 3/27/2017 6
Page:
27/03/2017

7. R&D Focus An evolving service
IMS LifeCycle • 3/27/2017 7

8. Sources of information Strength of the Editorial team
Team of around 15 in-house editors and free-lancers
Improved timeliness with strict guidelines and prioritisation process to include the information gathered in the service within certain timeframe.
Creation of specialist roles within the editorial team:with editors concentrating on company information, pipeline project and analysts predictions information.
IMS LifeCycle • 3/27/2017 8

9. Sources of Information Primary & Secondary
Primary research via:
Company interviews, with drug-specific questionnaires
Company R&D days & Company investor conferences
Scientific conferences (where specific ATCs are covered, I.e. neuroscience or oncology)
Business/Partnering conferences (where partnering forums are held and cover all ATCs
Attendance in the USA and Europe (where companies from all over the world are represented), and also in Japan and Australia.
Secondary research:
Analyst briefings
Conferences posters, conferences abstracts, review journals
Regulatory data from the various regulatory agencies such as the US FDA, EU EMEA and the Japanese NHI as well as Patents and other intellectual property sources
Online services and internet services
IMS LifeCycle • 3/27/2017 9

10. Example of a drug record
IMS LifeCycle • 3/27/2017 10

11. New Product Focus Introduction
The LifecCycle Training Course Introduction
New Product Focus Introduction
This IMS service covers new product launches by country, allowing for the evaluation of successful launch strategies world-wide.
New Product Focus is part of IMS LifeCycle, which enables the reviews of a drug life cycle at three critical stages: R&D stages, launch activities and patent protection worldwide.
IMS LifeCycle • 3/27/2017 11
Page:
27/03/2017

12. New Product Focus Statistics
Compendium of back data from 1982
Coverage of over 70 major markets
Over 280,000 launches with 178,000 distinct trade names, each of which representing a first launch in a country (first pack)
Biotechnology, Generics and excipients
NCEs (New Chemical Entities) - when and where a novel compound was first launched
Over 1,000 new pharmaceutical products reported every month
IMS LifeCycle • 3/27/2017 12

13. New Product Focus Data Content
New Product Focus records the very first launch of a product in
a particular country and identifies the indication and price at
the time of this initial launch; featuring:
Ingredient & Local trade name
Marketing company
Date & country of launch
Therapeutic class code & Indication (when available)
Composition (including form and dose)
Presentation (pack information)
Launch price data recorded in the local country currency but their level differ depending on the country, as follows:
Retail Selling Price (RSP), Retail Purchase Price (RPP), Manufacturers Selling Price (MSP), National Health Insurance (NHI); i.e. Japan, Average wholesale price (AWP); i.e. USA
Historical data - records not updated - hence always showing original companies and initial pack info at launch
IMS LifeCycle • 3/27/2017 13

14. New Product Focus Sources of information
Data collection methods vary from market to market.
In most industrialized countries, wholesaler to pharmacy transaction data is collected directly from wholesalers.
In other countries and for all hospital data, a representative sample is obtained and then projected to produce national estimates.
Regular validation studies are undertaken by IMS in conjunction with the pharmaceutical industry (EPHMRA).
New Product Focus identifies new chemical entities or new active substances by referring to R&D Focus, patents and regulatory data
IMS LifeCycle • 3/27/2017 14

15. New Product Focus Uses of a product launch information database
Comprehensive world-wide analysis of product launches
Monitor global product activity to track launches in all markets and sectors
Valuable pricing information
Benchmark product pricing strategy against market leaders, including pricing of generics
Unique on the market
Launch strategies
Search for key comparator drug launches to identify successful launch strategies of a product extension, looking at indication, or specific dose forms
IMS LifeCycle • 3/27/2017 15

16. Patent Focus Introduction
This IMS service provides evaluated patent information for marketed drugs and those in phase III and above active R&D, allowing the user to plan effectively for patent expiry far into the future.
Patent Focus is part of IMS LifeCycle, which enables the reviews of a drug life cycle at three critical stages: R&D stages, launch activities and patent protection worldwide
IMS LifeCycle • 3/27/2017 16

17. Different patent types per compound “Covering all angles”
Aim of originators is to cover the invention from all angles
Product patent
Claims the novel compound - generally most important
Process patent
Claims the process for preparing the compound e.g. gene expression technology to enhance the production of recombinant proteins
Method of use patent
Claims the method of treating/preventing a condition e.g. method for treating TNF-mediated inflammatory diseases, specifically arthritis
Composition patent
Claims the therapeutic compositions e.g. sustained release capsules
IMS LifeCycle • 3/27/2017 17

18. Patent Focus Statistics
Over 3,000 patent families with CAS (Chemical Abstracts Service) numbers
Over 139,000 patent records worldwide - with numbers, filing and estimated expiry dates
Covers 120 countries, including European Patent and applications
Covers biotech products: 17,800 patents records where mode of action is biotechnology
Covers patent extensions including Supplementary Protection Certificates (SPCs), Japanese and USA extensions (i.e. Paediatric exclusivities)
8,500 additions per year
IMS LifeCycle • 3/27/2017 18

19. Patent Focus Data content
Over 32 fields to search from including:
Product Synonyms (trade names)
Chemical Abstract Service (CAS) registry numbers
Patent originator
Therapy Class / Indication
Patent numbers and filing dates by country
Patent types (I.e. product, method of use, process, composition etc…)
Estimated patent expiry dates and SPCs by country
Commercial comments by country
Final product chemical structures
Please note: Patent Focus does not include Data Exclusivity data, featured in the Market Segmentation data.
IMS LifeCycle • 3/27/2017 19

20. Patent Focus Sources of information
Patent information emanates from official patent documentation relating to projects in development, either a patent application or a granted patent document
Close relationship with CAS, the Chemical Abstract Services (American Chemical Society) to maintain up-to-date records within the service
Close contact with patent attorneys at local country levels and work with official patent journals to reflect the latest amendments to the patent laws
Secondary resources, such as the Orange Book, official country patent journals, online and internet services are also monitored to update information on patent legal status, lapsing, granting, extensions, SPCs, paediatric exclusivities, marketing exclusivities, orphan drug status
IMS LifeCycle • 3/27/2017 20

21. Thank you for your attention
Ben Manning
Product Manager, Global Publications
3/27/2017